Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Mind Medicine (MindMed) Inc N.MMED


Primary Symbol: MNMD Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED.WR

Healthcare Psychedelics
Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen... see more

Recent & Breaking News (NDAQ:MNMD)

MindMed to Participate at Upcoming Investor Conferences

Business Wire June 1, 2023

MindMed Releases Investor Presentation Highlighting How the Company is Unlocking the Power of Psychedelics for Patients and Shareholders

Business Wire May 25, 2023

MindMed Publishes Report by Leading FDA Experts Validating MindMed's MM-120 Drug Development Strategy

Business Wire May 25, 2023

MindMed to Present Data on the Preclinical Activity of MM-402 at the American Society of Clinical Psychopharmacology (ASCP) 2023 Annual Meeting

Business Wire May 24, 2023

MindMed Announces Enrollment Milestone in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (GAD)

Business Wire May 17, 2023

MindMed Reports First Quarter 2023 Financial Results and Business Highlights

Business Wire May 4, 2023

MindMed Sends Letter to Shareholders Highlighting Company's Positive Momentum and Value-Enhancing Strategy

Business Wire May 2, 2023

MindMed to Host Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Business Update

Business Wire May 1, 2023

MindMed to Participate in May Investor Conferences

Business Wire April 26, 2023

MindMed Files Preliminary Proxy Statement for 2023 Annual Meeting

Business Wire April 18, 2023

MindMed Collaborators Announce Positive Topline Data from Phase 2 Trial of Lysergide (LSD) in Major Depressive Disorder (MDD)

Business Wire April 14, 2023

MindMed Appoints Mark R. Sullivan as Chief Legal Officer and Corporate Secretary

Business Wire April 13, 2023

MindMed Reports Full Year 2022 Financial Results and Business Highlights

Business Wire March 9, 2023

MindMed to Participate in March Investor Conferences

Business Wire February 28, 2023

Trippy Trading: Top Psychedelic Stocks For 2023

TheNewsWire January 17, 2023

MindMed Provides Corporate Update and 2023 Outlook

PR Newswire January 9, 2023

MindMed to Participate in the Canaccord Genuity New Paradigms and Treatment Approaches in Mental Health Conference

PR Newswire December 1, 2022

MindMed to Participate in the Jefferies London Healthcare Conference

PR Newswire November 11, 2022

MindMed Reports Third Quarter 2022 Financial Results and Business Highlights

PR Newswire November 10, 2022

MindMed to Host Earnings Call to Discuss Third Quarter 2022 Financial Results and Provide Business Update

PR Newswire November 3, 2022